Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 nov. 2014 07h30 HE | Source: Advaxis

Advaxis Submits Investigational New Drug Application for Phase 1/2 Study of ADXS-HPV and MedImmune's MEDI4736 for the Treatment of HPV-Associated Cervical and Head & Neck Cancer

PRINCETON, N.J., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company has submitted...
05 nov. 2014 07h30 HE | Source: Advaxis

Advaxis Submits Investigational New Drug Application for ADXS31-142 (ADXS-PSA) for the Treatment of Metastatic Castration Resistant Prostate Cancer

PRINCETON, N.J., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc.(Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company has submitted...
04 nov. 2014 08h00 HE | Source: Advaxis

Advaxis to Present Survival Data of Lm-LLO Cancer Immunotherapies in Recurrent Cervical Cancer and Canine Osteosarcoma at the Society for Immunotherapy of Cancer 29th Annual Meeting

Immunotherapy Candidate for Pediatric Osteosarcoma, ADXS-cHER2, Delays Metastatic Disease and Prolongs Overall Survival in Canine Osteosarcoma Bivalent Lm-LLO Immunotherapies Demonstrate...
30 oct. 2014 07h30 HE | Source: Advaxis

Advaxis's ADXS-cHER2 Immunotherapy Demonstrates T-Cell Immune Response in Data Analysis From Canine Osteosarcoma Study

PRINCETON, N.J., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that a data analysis of its...
20 oct. 2014 07h30 HE | Source: Advaxis

Advaxis Appoints David J. Mauro, M.D., Ph.D., as Chief Medical Officer

PRINCETON, N.J., Oct. 20, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed David J....
15 oct. 2014 07h30 HE | Source: Advaxis

Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer

PRINCETON, N.J., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced preliminary data from its...
14 oct. 2014 07h30 HE | Source: Advaxis

Advaxis's Lm-LLO Immunotherapy Data to be Presented in Three Posters at the Society for Immunotherapy of Cancer 29th Annual Meeting

PRINCETON, N.J., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a cancer immunotherapy company, today announced that preclinical and clinical data highlighting the potential of its...
08 oct. 2014 07h30 HE | Source: Advaxis

Advaxis Appoints World Renowned Oncologist and Research Scientist, Dr. Samir N. Khleif, to Its Board of Directors

PRINCETON, N.J., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced the appointment of world renowned...
01 oct. 2014 09h30 HE | Source: Advaxis

Advaxis's Chief Scientific Officer, Dr. Robert Petit, Leads Panel Discussion on Combination Immunotherapies

PRINCETON, N.J., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that Dr. Robert Petit, its Chief...
26 sept. 2014 07h30 HE | Source: Advaxis

Advaxis's Cancer Immunotherapy Featured on Fox News

PRINCETON, N.J., Sept. 26, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that ADXS-cHER2, its proprietary Lm-LLO...

Page précédente